|1.||Schmitt, Hubert J: 3 articles (05/2009 - 02/2006)|
|2.||Nielsen, C V: 2 articles (07/2015 - 07/2015)|
|3.||Thomsen, J L: 2 articles (07/2015 - 07/2015)|
|4.||Gätke, M R: 2 articles (07/2015 - 07/2015)|
|5.||Mabboux, Isabelle: 2 articles (09/2014 - 01/2014)|
|6.||Ceppa, Franck: 2 articles (09/2014 - 01/2014)|
|7.||Lockridge, Oksana: 2 articles (01/2014 - 07/2006)|
|8.||Martyn, J A J: 2 articles (05/2011 - 10/2002)|
|9.||Zencirci, Beyazit: 2 articles (01/2010 - 01/2009)|
|10.||Habre, Walid: 2 articles (12/2008 - 07/2006)|
10/01/2002 - "In contrast to previous studies with non-depolarizers in burned patients, normal mivacurium doses can produce paralysis, at least as rapidly as in controls, but with a possibility of a prolonged recovery from block. "
05/01/2005 - "The quantitative distinction between train-of-four "counts of 2" and posttetanic "counts of 2" evidenced by a stable paralysis/stable infusion rate method in anesthetized patients receiving mivacurium."
02/01/2005 - "The following case study describes causality and interventions for a patient with prolonged paralysis after receiving mivacurium."
02/01/2005 - "Prolonged paralysis has occurred 3 times in the past 2 years at this pediatric hospital after administration of mivacurium. "
02/01/2005 - "Prolonged paralysis related to mivacurium: a case study."
|2.||Eye Diseases (Eye Disease)
05/01/1998 - "Forty patients without eye disease, undergoing elective nonophthalmic surgery, were studied in a double-blind, randomised, placebo-controlled study evaluating the efficacy of mivacurium pretreatment in attenuating the rise in intra-ocular pressure in response to suxamethonium administration, laryngoscopy and intubation. "
12/01/2001 - "Arterial blood pressure declined and 13/30 patients manifested erythema following mivacurium administration. "
03/01/1995 - "One patient exhibited a 54% decrease in mean arterial pressure, generalized erythema and bronchospasm after mivacurium 0.2 mg kg-1. "
12/01/2001 - "Equi-lasting doses of rocuronium resulted in favourable intubating conditions more rapidly, improved hemodynamic stability, required less frequent administration of maintenance doses and were not associated with erythema, compared to mivacurium."
03/01/1995 - "Erythema developed in two, three and seven patients after atracurium, mivacurium 0.15 mg kg-1 and mivacurium 0.2 mg kg-1, respectively. "
03/01/1989 - "Facial erythema, decrease in blood pressure, and elevation of histamine level were all accentuated by increasing the dose of mivacurium and by more rapid injection of the drug. "
05/01/1998 - "However, mivacurium decreased the incidence of swallowing, coughing, movement and laryngospasm (p < 0.05). "
05/01/2000 - "However, an equally critical issue is whether there is a reliable replacement for succinylcholine for the treatment of laryngospasm or for rapid sequence induction in patients with "full stomachs." Succinylcholine produces more intense block in a shorter time at the laryngeal muscles, compared with the adductor pollicis, compared with vecuronium, rocuronium, mivacurium, and rapacuronium (30). "
01/01/1999 - "To compare the efficacy of low dose (LD) mivacurium (0.08 mg.kg-1) with LD succinylcholine (0.5 mg.kg-1) in modifying seizure activity during electroconvulsive therapy (ECT). "
01/01/1999 - "Seizure modification was better (mean (range)) after succinylcholine 2.06(1-3) than after mivacurium 2.56(2-4) (P < 0.05). "
|2.||Succinylcholine (Suxamethonium Chloride)
|3.||rocuronium (rocuronium bromide)
|4.||Neostigmine (Neostigmine Bromide)
|7.||Cocaine (Cocaine HCl)
|8.||Vecuronium Bromide (Vecuronium)
|5.||Artificial Respiration (Mechanical Ventilation)